Imara-Logo-Color-RGB.jpg
Imara Announces Stockholder Approval of Merger With Enliven
February 22, 2023 16:01 ET | Imara, Inc.
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc....
Imara-Logo-Color-RGB.jpg
Enliven Therapeutics and Imara Announce Merger Agreement
October 13, 2022 16:35 ET | Imara, Inc.
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of...
Imara-Logo-Color-RGB.jpg
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 05, 2022 06:45 ET | Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara-Logo-Color-RGB.jpg
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET | Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 08, 2022 07:00 ET | Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET | Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 25, 2022 07:00 ET | Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
Imara-Logo-Color-RGB.jpg
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET | Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara-Logo-Color-RGB.jpg
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET | Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET | Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...